Grant Yonehiro
About Grant Yonehiro
Chief Business Officer at Bolt Biotherapeutics
Grant Yonehiro has served as the Chief Business Officer at Bolt Biotherapeutics since joining the company in 2016. His role encompasses overseeing the company's business operations, strategy, and development initiatives within the biotechnology sector. Bolt Biotherapeutics focuses on developing advanced biotherapeutic treatments, and Yonehiro's extensive background in business development and commercialization is integral to its strategic growth and operational success.
Career Journey in Biotechnology Companies
With over 25 years of experience, Grant Yonehiro has played pivotal roles in several biotechnology firms. He served as president and CEO of Perseid Therapeutics, guiding the company from its inception to its acquisition by Astellas Pharma. Post-acquisition, he remained as president of an Astellas operating site. Yonehiro has held senior management positions at GenVec, Inc., Berkeley Lights, and Maxygen Inc., contributing in various capacities including commercial operations, product management, and drug development.
Educational Background of Grant Yonehiro
Grant Yonehiro holds a Bachelor of Individualized Studies, graduating magna cum laude from the University of Minnesota. He further pursued his education by earning an MBA from the Haas School of Business at the University of California, Berkeley. His academic background underpins his proficiency and strategic insight within business and corporate management in the biotechnology industry.
Professional Experience Beyond Biotechnology
In addition to his roles within biotechnology companies, Grant Yonehiro has diverse professional experience. He worked in business development at Cell Genesys, Inc. and in investment banking at Piper Jaffray. Additionally, he contributed to technology transfer initiatives at Lawrence Berkeley National Laboratory. These roles have broadened his expertise in business strategy and corporate development.